<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4695">
  <stage>Registered</stage>
  <submitdate>4/11/2014</submitdate>
  <approvaldate>4/11/2014</approvaldate>
  <nctid>NCT02288585</nctid>
  <trial_identification>
    <studytitle>The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus</studytitle>
    <scientifictitle>The Effect of a Low-fat Spread Enriched With Plant Sterol Esters on the Blood Lipid Profile of Subjects With Established Type 2 Diabetes Mellitus and Subjects at High Risk of Developing Type 2 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FDS-SCC-1552</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vascular Diseases</healthcondition>
    <healthcondition>Hypercholesterolemia</healthcondition>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Plant sterols
Other interventions - Placebo product

Active Comparator: Plant sterols - Plant sterols

Placebo Comparator: Placebo product - Placebo product


Other interventions: Plant sterols
Plant sterols

Other interventions: Placebo product
Placebo product

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in TG concentrations</outcome>
      <timepoint>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in LDL-C</outcome>
      <timepoint>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in blood lipids</outcome>
      <timepoint>At baseline (after 2 weeks run-in period) and after 6 weeks intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Triglycerides &gt;150 mg/dL or 1.74 mmol/L

          -  LDL-cholesterol: Subjects at high risk for developing T2DM: 115-190 mg/dL or 2.95-4.94
             mmol/L. Subjects with established T2DM that are on statins: 85-190 mg/dL or 2.15-4.94
             mmol/L.

          -  HbA1c: Subjects at high risk for developing T2DM: &lt;6.50% or = 48 mmol/mol. Subjects
             with established T2DM: = 8.5% or = 69 mmol/mol.

          -  BMI &gt; 20.0 kg/m2.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Recently (within 1 year) diagnosed with cardiovascular event(s) (stroke, TIA, angina,
             myocardial infarction, heart failure), systemic inflammatory conditions

          -  Use of over-the-counter and prescribed medication which may interfere with study
             measurements (i.e. ezetimibe, fibrates and Niacin), to be judged by the principal
             investigator.

          -  Currently smoking or being a non-smoker for less than 6 months and reported use of any
             nicotine containing products in the 6 months prior to screening and/or during the
             study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>150</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>CSIRO - Adelaide</hospital>
    <hospital>CSIRO, North Ryde - Sydney</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Unilever R&amp;D</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>CSIRO</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Double-blind, randomised, placebo-controlled, parallel group study with two intervention
      arms. The study will be conducted in 150 subjects and the primary objective is to show a
      fasting LDL-cholesterol and triglyceride lowering effect of plant sterols in subjects with
      established type 2 diabetes mellitus and subjects at high risk of developing type 2 diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02288585</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Manny Noakes</name>
      <address>CSIRO</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>